PD45-09 IDENTIFYING SITES OF PROSTATE CANCER RECURRENCE IN 68 Ga-PSMA PET/CT BASED ON SCAN INDICATION

You have accessJournal of UrologyProstate Cancer: Staging II (PD45)1 May 2024PD45-09 IDENTIFYING SITES OF PROSTATE CANCER RECURRENCE IN 68Ga-PSMA PET/CT BASED ON SCAN INDICATION Maya N. Ataya, Clint D. Bahler, Michael O. Koch, Mark Tann, Mark A. Green, Heather L. Huelster, Ethan L. Ferguson, and Shayan Ahmad Maya N. AtayaMaya N. Ataya , Clint D. BahlerClint D. Bahler , Michael O. KochMichael O. Koch , Mark TannMark Tann , Mark A. GreenMark A. Green , Heather L. HuelsterHeather L. Huelster , Ethan L. FergusonEthan L. Ferguson , and Shayan AhmadShayan Ahmad View All Author Informationhttps://doi.org/10.1097/01.JU.0001008792.09108.b4.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET) has emerged as a crucial method for evaluating individuals experience biochemically recurrent (BCR) prostate cancer. This study aims to identify and contrast sites of recurrence using PSMA-PET imagining, depending on the scan's indication. METHODS: Our study retrospectively analyzed individuals who had undergone PSMA-PET scans at Indiana University Hospital between May 2015 and November 2021. The analysis revealed 347 patients who had received PSMA-PET scans due to biochemical recurrence. These patients were categorized according to the scan's indication: 166 patients for BCR post prostatectomy, 66 patients for BCR post-radiation, 75 patients for BCR post prostatectomy and radiation, and 40 patients for Stage 4, defined as those who had undergone chemotherapy or showed evidence of distant metastasis on other imaging modalities. RESULTS: Positive scans were observed in 60% of patients with BCR following prostatectomy, 86% of patients after radiation, 66% in patients after prostatectomy and radiation, and 95% of patients classified as stage 4. Among patients with biochemical recurrence following prostatectomy, the most frequent site of recurrence was the bone (18%), followed by local lymph nodes (16%) and the prostate fossa (13%). For patients experiencing biochemical recurrence after radiation, the prostate (33%) was the most prevalent site of recurrence, followed by bone (22%). Moreover, for patients who had BCR after prostatectomy and salvage radiation, the bone was also the most common site of recurrence (18.6%), followed by local lymph nodes (16%). Among patients in the Stage 4 category, the most common site of recurrence was the bone (50%), followed by visceral metastases (20%). CONCLUSIONS: The site of prostate cancer recurrence varied by indication. Notably, after prostatectomy monotherapy only 13% of scans where positive in the prostate fossa alone while 18% were positive in bone. For post radiation failures, the most common site was the prostate at 33%. PSA recurrence after prostatectomy with salvage radiation tended to be distant lymph nodes (15%), bone (19%), or visceral (15%). Source of Funding: Telix Pharmaceuticals and Al Christy Prostate Cancer Foundation © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e970 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Maya N. Ataya More articles by this author Clint D. Bahler More articles by this author Michael O. Koch More articles by this author Mark Tann More articles by this author Mark A. Green More articles by this author Heather L. Huelster More articles by this author Ethan L. Ferguson More articles by this author Shayan Ahmad More articles by this author Expand All Advertisement PDF downloadLoading ...